Previous Article | Next Article ![]()
Molecular and Cellular Biology, November 2001, p. 7442-7448, Vol. 21, No. 21
MRC Functional Genetics
Unit,3 Department of Human Anatomy and
Genetics,1 University of Oxford, Oxford OX1
3QX, and Centre for Genome Research, The University of
Edinburgh, Edinburgh EH9 3JQ,2 United
Kingdom
Received 27 July 2001/Accepted 31 July 2001
Dystrobrevins are a group of
dystrophin-associated proteins that have significant sequence homology
with the cysteine-rich C-terminal region of dystrophin, the product of
the X-linked Duchenne muscular dystrophy (DMD) gene. This region
of similarity can be divided into several protein-binding
domains, namely a ZZ domain, one or two syntrophin binding sites, and
two tandem The dystrobrevin protein family comprises Gene targeting construct.
An 18-kb genomic fragment
containing Generation of dtnb
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.21.7442-7448.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Role of
-Dystrobrevin in Nonmuscle
Dystrophin-Associated Protein Complex-Like Complexes in Kidney
and Liver


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-Dystrobrevin is a dystrophin-related and -associated protein
that is highly expressed in brain, kidney, and liver. Recent studies
with the kidneys of the mdx3Cv mouse, which lacks all dystrophin isoforms, suggest that
-dystrobrevin, and not the dystrophin isoforms, may be the key component in the assembly of
complexes similar to the muscle dystrophin-associated protein complexes
(DPC) in nonmuscle tissues. To understand the role of
-dystrobrevin
in the function of nonmuscle tissues, we generated
-dystrobrevin-deficient (dtnb
/
) mice by
gene targeting. dtnb
/
mice are healthy,
fertile, and normal in appearance. No
-dystrobrevin was detected in
these mice by Western blotting or immunocytochemistry. In addition, the
levels of several
-dystrobrevin-interacting proteins, namely Dp71
isoforms and the syntrophins, were greatly reduced from the basal
membranes of kidney tubules and liver sinusoids and on Western blots of
crude kidney and liver microsomes of
-dystrobrevin-deficient mice.
However, no abnormality was detected in the ultrastructure of membranes
of kidney and liver cells or in the renal function of these mice.
-Dystrobrevin may therefore be an anchor or scaffold for Dp71 and
syntrophin isoforms, as well as other associating proteins at the basal
membranes of kidney and liver, but is not necessary for the normal
function of these mice.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-helical coiled coils. The syntrophin binding sites
mediate interaction with the syntrophins, a family of modular adapter
proteins, while the N-terminal
-helical coiled coil binds with the
reciprocal region of dystrophin isoforms and utrophin, the autosomal
homologue of dystrophin (1, 7, 16, 20).
- and
-dystrobrevin.
-Dystrobrevin is expressed predominantly in skeletal muscle, heart, brain, and lung (4, 19). Differential splicing
of the
-dystrobrevin message results in three
successively C-terminal-truncated isoforms in skeletal and cardiac
muscle (4, 14). In skeletal muscle,
-dystrobrevin is
part of a multimolecular dystrophin-associated protein complex (DPC)
that connects the actin cytoskeleton and the extracellular matrix
(ECM). This bridge is thought to be important for protecting the
muscle membrane from stresses incurred during contraction and
relaxation. The DPC can be divided into three subcomplexes,
namely the membrane-spanning dystroglycan complex, the muscle-specific
sarcoglycan complex, and the cytoplasmic complex that comprises
-dystrobrevin, syntrophin, and dystrophin. In DMD muscle, the
absence of dystrophin results in muscle degeneration that is
coupled with a dramatic reduction of the DPC from the sarcolemma
(1). In contrast, targeted disruption of the
-dystrobrevin gene in the mouse leads to mild muscular dystrophy
that does not interfere with the assembly of the DPC at the sarcolemma.
Since the cytoskeleton-ECM connection is not disrupted, it
has been proposed that the muscle degeneration observed in
-dystrobrevin-deficient mice (adbn
/
mice)
is due to deficiency in intracellular signaling mediated by
-dystrobrevin (9). At the postsynaptic membrane of
neuromuscular junctions (NMJs) of skeletal muscle,
-dystrobrevin
associates with two complexes: the DPC at the troughs and with utrophin
in a complex not unlike the DPC, but at the crests. The NMJs of
abdn
/
mice mature abnormally, suggesting
-dystrobrevin is required for the maturation of the postsynaptic
membrane (10). In brain,
-dystrobrevin-1 is present in
the glia and microvasculature (2, 3). The effect of
-dystrobrevin deficiency in this tissue is not known.
-Dystrobrevin is a dystrophin-associated protein of unknown function
that is expressed in a wide variety of nonmuscle tissues, but is found
most abundant in brain, kidney, liver, and lung. In brain,
-dystrobrevin associates with dystrophin in hippocampal and Purkinje
neurons and is found highly enriched in postsynaptic densities
(2, 3). This finding is important, since approximately a
third of DMD patients have cognitive impairment. In kidney,
-dystrobrevin is part of several different DPC-like complexes that
are localized in a cell-type-specific manner (12). In
mdx3Cv mice that lack all known dystrophin isoforms,
-dystrobrevin expression and localization at the membrane in brain
and kidney are not affected. Thus, it has been speculated that this
protein may be the key regulator of DPC-like complex formation and
maintenance in nonmuscle tissues (2, 12). The
-dystrobrevin gene (Dtnb) has been mapped to the proximal
region of mouse chromosome 12 and human chromosome 2p22-23 (11,
18). To date, this gene is not associated with any known genetic
disorder. To investigate into the function of the protein, a mouse
deficient for the
-dystrobrevin protein was generated by targeted
disruption of the Dtnb gene.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-dystrobrevin coding exons 1, 2, and 3 was isolated from
a mouse 129/SvJ genomic library in lambda FIX II (Stratagene) by
using a 5'-end mouse
-dystrobrevin cDNA clone. A 5.5-kb
EcoRI fragment comprising exon 3 flanked by 3 and 2.5 kb of
intronic sequence upstream and downstream, respectively, was subcloned
into pGEM7Zf(+) (Promega). A
(TAG)3/IRES/lacZ/SV40pA/MC1neopA (15) cassette was inserted into the EcoRV site
of the exon. Two hundred micrograms of the targeting construct was
linearized with XhoI and purified with Geneclean III (BIO
101) prior to electroporation.
/
mutant mice.
One-hundred-fifty- and 50-µg samples of linearized targeting
construct were introduced into 5 × 107 E14-TG2a.IV
embryonic stem (ES) cells by electroporation (800 V, 3 µF in
phosphate-buffered saline). Recombinant ES cells were selected for G418
resistance. A total of 600 colonies were isolated and cultured in
96-well plates. The correct targeting events were determined by
Southern blot analysis of BamHI- and
EcoRV-digested ES cell DNA with probes 5' and 3' to the
targeted site (Fig. 1A). Three clones
containing the correct targeting event were injected into C57BL/6
blastocysts, which were then transferred into pseudopregnant females.
Thirteen chimeras were produced, of which 12 were male, and all were 80 to 90% chimeric by coat color. Four male chimeras from the three
clones were bred with C57BL/6 females, and germ-line transmission was
determined by Southern blot analysis of DNA from tail biopsies of
agouti coat-colored offspring. dtnb+/
mice
derived from the test crosses were mated to produce
dtnb
/
offspring at a ratio of 1:4. All mice
used in subsequent analyses were over 8 weeks old.

View larger version (30K):
[in a new window]
FIG. 1.
(A) Targeted inactivation of the mouse
-dystrobrevin
gene. Restriction map of the wild-type allele of the Dtnb
gene, the targeting vector, and the predicted product of homologous
recombination. An open box represents the targeted exon. The external
probes used for the Southern blot analyses are shown. B,
BamHI; RI, EcoRI; RV, EcoRV; S,
SacI. (B) Genotype analyses of offspring from heterozygote
matings. The top panel shows a Southern blot of
EcoRV-digested genomic DNA from tail biopsies probed with a
1.2-kb EcoRV-EcoRI DNA fragment external to the
targeted site (probe A). The wild-type allele produces a ~10.3-kb
band, while the mutant allele produces a ~12-kb band. The middle and
bottom panels show the products of PCR amplification of the mutant and
wild-type alleles, respectively, of the same DNA samples.
Genotyping. Mice were genotyped by Southern blot or PCR analysis of DNA from tail biopsies. For Southern blot analysis, DNA from tail biopsies was digested with EcoRV with or without a second digestion with BamHI, resolved on a 1% agarose gel, and transferred onto Hybond N+ membrane (Amersham Pharmacia). Blots were probed with either a 1.2-kb EcoRV-EcoRI 5' probe (probe A) for EcoRV-digested DNA or a 0.7-kb SacI-BamHI 3' probe (probe B) for EcoRV-BamHI-digested DNA. PCR analyses of DNA from tail biopsies were performed as follows. The mutant allele was amplified with the IRES T3' primer (5'GATTCGCAGCGCATCGCCTTC) and the 487R primer (5'TGTCGTAGGCGGCGACCAT), while the wild-type allele was amplified with the 5'Ex3 primer (5'TGTCCAGTTGTGAGGTGACAC) and the 487R primer. Both PCRs were performed under the following cycling conditions: 1 cycle of 94°C for 4 min, 58°C for 2 min, and 72°C for 6 min, followed by 30 cycles of 94°C for 50 s, 58°C for 50 s, and 72°C for 50 s, and then 1 cycle of 94°C for 2 min, 58°C for 2 min, and 72°C for 6 min.
Antibodies.
All antibodies mentioned in this paper have been
described previously:
CT-FP (anti-
-dystrobrevin and
anti-
-dystrobrevin-1 and -2) and
1CT-FP
(anti-
-dystrobrevin-1) (3);
521
(anti-
-dystrobrevin), URD40 (antiutrophin), 2166, which was
raised against the last 17 amino acids of mouse dystrophin
(antidystrophin, Dp71), and 2401, which was raised against the
alternatively spliced C terminus of dystrophin (anti-Dp71
C)
(2); and isoform-specific antisyntrophin antibodies 2688 (anti-
-syntrophin), 2689 (anti-
1-syntrophin), and 2045 (anti-
2-syntrophin) (12). Antiactin antibody was
purchased from Sigma-Aldrich (catalog no. A2066).
Western blot analysis.
Protein extracts were prepared
essentially as described in reference 12. Briefly, fresh
frozen tissues were homogenized in treatment buffer (75 mM Tris-HCl
[pH 6.8], 4 M urea, 3.8% sodium dodecyl sulfate (SDS), 20%
[vol/vol] glycerol, 5% [vol/vol] 2-mercaptoethanol). Twenty
micrograms of proteins from each tissue were separated on
SDS-polyacrylamide gel electrophoresis (PAGE) gels (8%
polyacrylamide) and transferred onto nitrocellulose membranes
(Schleicher and Schuell) in transfer buffer (20% ethanol, 0.1% SDS,
192 mM glycine, 25 mM Tris-HCl [pH 8.5]). Membranes were blocked in
5% milk powder in Tris-buffered saline-Tween 20 (TBST; 150 mM NaCl,
50 mM Tris-HCl [pH 7.5], 0.1% Tween 20) for an hour. Blots were
incubated for an hour at room temperature with antibodies in 5%
milk-TBST solution at the following concentrations:
CT-FP, 1:1,000;
1CT-FP, 1:3,000; URD40, 1:250; 2166, 1:500; or 2401, 1:50. Blots
were subsequently washed twice in TBST and twice in 5% milk-TBST for
5 min each. Horseradish peroxidase-conjugated donkey anti-rabbit
antibodies (Jackson ImmunoResearch) were applied at 1:3,000 in 5%
milk-TBST for 1 h at room temperature after which the membranes
were washed four times in TBST. Bound antibodies were detected with a
BM chemiluminescence detection kit (Roche).
Microsome preparation and analysis.
Crude microsomes from
dtnb+/+ and dtnb
/
kidneys and liver were prepared in the following manner. Fresh frozen
kidneys and liver were homogenized in 2 or 4 ml of ice-cold microsome
buffer containing 300 mM sucrose, 10 mM PIPES
[piperazine-N, N'-bis(2-ethanesulfonic acid)]
(pH 6.8), 10 mM NaCl, 3 mM MgCl2, 1 mM EGTA, and protease inhibitors (Complete; Roche). Homogenates were centrifuged at 700 × g for 10 min at 4°C to pellet the nuclear
fraction. The postnuclear supernatant was passed through a sieve with
pore size of 40 µm (Falcon) and then centrifuged at
141,000 × g at 4°C for 45 min with an SW41 Ti rotor
(Beckman) to pellet insoluble material. The supernatant was carefully
removed, and the pellet was homogenized in half of the original volume
of ice-cold microsome buffer. Thirty micrograms of microsomes was
separated on SDS-PAGE gels (8% polyacrylamide) and processed for
Western blot analysis with the
CT-FP (1:1,000),
1CT-FP (1:3,000),
URD40 (1:250), 2166 (1:500), 2401 (1:50), 2689 (1:250), and antiactin
(1:500) antibodies.
Immunofluorescence analysis.
Ten-micrometer cryosections of
kidneys and liver were processed for immunofluorescence labeling as
previously described (12). Slides were incubated for
1 h at room temperature in primary antibodies diluted in TBS (150 mM NaCl, 50 mM Tris-HCl [pH 7.5]) at the following dilutions:
521,
1:200;
1CT-FP, 1:250; URD40, 1:250; 2401, 1:20; 2688, 1:50; 2689, 1:200; and 2045, 1:100. This was followed by incubation with rhodamine
red-X-conjugated donkey anti-rabbit antibodies (Jackson ImmunoResearch)
at a dilution of 1:100. Washed slides were mounted in Vectashield
(Vector Laboratories), visualized with a Leica DMRE fluorescence
microscope, and photographed with a Leica DMLD camera. For direct
comparison of fluorescence intensity, dtnb+/+
and dtnb
/
tissues were photographed under
identical settings.
Urine analysis. Spot urine samples were obtained from mice >6 months old and assayed for creatinine, protein, calcium, and glucose levels on the day of sampling. Urine creatinine was measured by using the alkaline picrate colorimetric assay (Sigma-Aldrich). Total protein was measured by using the Bio-Rad protein assay kit. Calcium levels were measured with the calcium-cresolphthalein colorimetric assay (Sigma-Aldrich). Glucose was measured with the Infinity glucose reagent (Sigma-Aldrich). All assays were performed according to the manufacturer's instructions. Urine samples were diluted 1:20 in deionized water for creatinine and protein assays. Ratios of urine protein to creatinine, calcium to creatinine, and glucose to creatinine were used as indices of proteinuria, calciuria, and glucouria, respectively. The data are presented as means ± standard errors. The statistical significance of the difference between mean values of test and control groups was assessed by using the two-tailed Student's t test. Differences between mean values of mutant and control groups were considered significant when the P value was <0.05.
| |
RESULTS |
|---|
|
|
|---|
Generation of dtnb
/
mice and their
phenotype.
The
-dystrobrevin gene spans over 130 kb and
comprises at least 21 exons, 5 of which are alternatively spliced in a
tissue-specific manner. Furthermore, there is evidence that this gene
is regulated by at least two promoters (11). To ensure
that all known
-dystrobrevin isoforms were disrupted, a
(TAG)3/IRES/lacZ/SV40pA/MC1neopA
(15) cassette was inserted into exon 3, which encodes part
of the EF hand region that is present in all known
-dystrobrevin
isoforms, to disrupt the reading frame (Fig. 1A). This cassette
contains stop codons in three open reading frames at the 5' end of the internal ribosome entry site (IRES) cassette to ensure that only a
truncated form of the
-dystrobrevin protein is produced. The mutation was introduced into ES cells by homologous recombination. Matings between chimeric male mice and C57BL/6 female mice produced heterozygous offspring, indicating that the mutation was transmitted through the germ line. Matings between heterozygous mice produced offspring that were wild type and heterozygous or homozygous for the
mutation (Fig. 1B) at a ratio of 1:2:1.
) and
homozygous (dtnb
/
) for the mutant gene
were viable, fertile, and indistinguishable from their wild-type
littermates. Histological examination of various tissues by hematoxylin
and eosin staining revealed no gross morphological abnormality
(data not shown). No
-dystrobrevin was detected in the
dtnb
/
tissues either on Western blots or by
immunofluorescence examination (Fig. 2A,
3A', and 4A'). Levels of
-dystrobrevin in
dtnb+/
tissues were reduced by up to half of
the levels seen in dtnb+/+ tissues, showing that
in normal tissues, both copies of the gene are active (Fig. 2A). To
analyze the effect of
-dystrobrevin loss on the levels of other
dystrophin-related proteins and isoforms, Western blot analyses were
performed with the same samples with antibodies against
-dystrobrevin-1, utrophin, and two C-terminal splice forms of
dystrophin and Dp71. No difference could be detected in the levels of
any of the proteins in brain or liver (Fig. 2B to E). However, in
dtnb
/
kidney, there appeared to be a
moderate increase in
-dystrobrevin-1 (Fig. 2B), while levels of Dp71
and Dp71
C were noticeably reduced (Fig. 2D and E).
|
-Dystrobrevin loss affects the localization of Dp71
C and
syntrophins at the basal region of cortical renal tubules and liver
sinusoids.
To analyze the effect of
-dystrobrevin deficiency on
the distribution of dystrophin-related and associated proteins,
we performed immunofluorescence analyses of
dtnb+/+ and dtnb
/
kidneys by using isoform-specific antibodies. In normal kidney,
-dystrobrevin is present in glomeruli, Bowman's capsules, and the
basolateral membranes of cortical renal tubules and collecting ducts,
whereas
-dystrobrevin-1 is restricted to the glomeruli, blood
vessels, and a subset of cortical renal tubules (Fig. 3A and
B) (12).
As expected no
-dystrobrevin was detected in
dtnb
/
kidneys (Fig. 3A'). Surprisingly, in
light of the increase in the overall level of
-dystrobrevin-1 in
dtnb
/
kidney, no difference was detected in
the localization of
-dystrobrevin-1 in
dtnb
/
kidney by immunofluorescence. Nor was
there any obvious increase in overall staining intensity with the
1CT-FP antibody (Fig. 3B'). Thus, the moderate increase in
-dystrobrevin-1 on Western blots of dtnb
/
kidney is not due to compensation for the absence of
-dystrobrevin in renal tubules and collecting ducts.
|
-dystrobrevin colocalizes and
coimmunoprecipitates with utrophin, Dp71
C, and the syntrophins in
normal kidney (12). Here, we found no difference in
utrophin staining in control and dtnb
/
kidneys (Fig. 3C and C'). In contrast, Dp71
C, which is present in
the basal regions of normal cortical renal tubules (Fig. 3D), was
markedly reduced or undetectable in corresponding regions of
dtnb
/
kidneys. Similar results were observed
with
-syntrophin (Fig. 3E and E') and
2-syntrophin (Fig. 3F and
F') in this region. In addition,
2-syntrophin staining was lost from
collecting ducts (Fig. 3G and G'), but not from glomeruli of
dtnb
/
kidneys (Fig. 3F and F').
-Syntrophin staining in collecting ducts was unchanged (data not
shown). The persistence of
2-syntrophin at the glomerulus
could be due to the presence of
-dystrobrevin-1 or utrophin, while
the retention of
-syntrophin in collecting ducts may be due to
utrophin or another membrane-associated protein. In normal kidney,
1-syntrophin is found in blood vessels, a subset of cortical renal
tubules, and corticomedullary collecting tubules (Fig. 3H and I). In
the dtnb
/
kidneys, there was a marked
decrease in
1-syntrophin staining from the latter two structures,
but levels were unaltered in blood vessels (Fig. 3H' and I').
To determine if
-dystrobrevin loss had a similar effect on its known
ligands in liver, a similar study was conducted with liver
cryosections of control and dtnb
/
mice. In normal liver,
-dystrobrevin, Dp71
C, and
1-syntrophin are localized at the sinusoids and/or at the sinusoidal
face of hepatocytes, but not in capillaries or large blood vessels
(Fig. 4A, D, and E). Conversely,
-dystrobrevin-1 is found in capillaries and large blood vessels, but
not in sinusoids (Fig. 4B), while utrophin is present in both sinusoids
and larger blood vessels (Fig. 4C). As expected,
-dystrobrevin was
undetectable in dtnb
/
liver (Fig. 4A').
Again, distribution of
-dystrobrevin-1 and utrophin was unaltered in
dtnb
/
liver (Fig. 4B' and C'). However, no
Dp71
C staining was detectable at the sinusoids, while the intensity
of
1-syntrophin staining was reduced to a third of that seen in
control liver (Fig. 4D' and E').
|
-Dystrobrevin facilitates membrane association of Dp71 isoforms
in kidney and liver.
To confirm our immunofluorescence findings,
we prepared microsomes from kidney and liver of control and
dtnb
/
mice and analyzed their protein
content by Western blotting. As predicted,
-dystrobrevin was
detected at high levels in microsomes prepared from kidney and liver of
control mice, but not dtnb
/
mice (Fig.
5A). In agreement with the
immunofluorescence data, no obvious difference was seen in the levels
of
-dystrobrevin-1 or utrophin between control and
dtnb
/
kidney microsomes or the levels of
utrophin between control and dtnb
/
liver
microsomes (Fig. 5B and C). In contrast, there was at least a twofold
decrease in the levels of Dp71
C and
1-syntrophin in dtnb
/
kidney microsomes and in the levels of
the Dp71 isoforms and
1-syntrophin in
dtnb
/
liver microsomes compared with the
levels of these proteins in corresponding control tissues (Fig. 5D to
F). These findings suggest that the loss of immunofluorescence staining
observed in dtnb
/
kidney and liver is
connected with their disassociation from the membrane. Levels of actin,
a protein not known to interact with
-dystrobrevin, were not
noticeably different in microsomes of dtnb
/
and wild-type tissues (Fig. 5G).
|
Urine and ultrastructural analyses.
To identify possible
changes in renal function resulting from this mutation, spot urine
samples were obtained from dtnb
/
mice and
their heterozygous and wild-type littermates and analyzed for abnormal
levels of proteinuria, calciuria, and glucouria. The results of our
findings are tabulated in Table 1. The
differences in protein/creatinine and calcium/creatinine ratios from
all groups were not statistically significant. The glucose/creatinine
ratios in samples from male and female mice of the
dtnb+/
and dtnb
/
groups were not significantly different. The glucose/creatine value of
the samples from female dtnb
/
mice was
significantly different from that of wild-type females at P < 0.05. This could be due to the small sample size, since the
differences between glucose/creatinine ratios of wild-type and
dtnb
/
male mice and the differences between
the pooled data from male and female mice were found to be not
significant (P > 0.7 for pooled data).
|
-dystrobrevin led to ultrastructural
changes in kidney and liver cells, dtnb
/
and
control kidneys and liver were examined by electron microscopy. We
could find no obvious difference in the ultrastructure of the basolateral membranes of tubular epithelia and podocyte foot processes in kidney or in the ultrastructural features of the sinusoids or the
sinusoidal face of hepatocytes in liver of
dtnb
/
mice (data not shown).
| |
DISCUSSION |
|---|
|
|
|---|
We have generated mice with a targeted mutation in exon 3 of the
-dystrobrevin gene.
-Dystrobrevin was undetectable in tissues from mice that were homozygous for the mutation by Western blotting and
immunohistochemistry, confirming that this mutation abolishes all known
-dystrobrevin isoforms. Despite the expression of
-dystrobrevin in many tissues, dtnb
/
mice are viable,
fertile, and show no obvious histological abnormality. Limited
investigation of urine samples has so far revealed no functional
significance of this mutation to the kidney. Normal expression of
-dystrobrevin-1 in dtnb
/
kidney and liver
suggests that
-dystrobrevin-1 is not compensating for the absence of
-dystrobrevin in these tissues.
One similarity between the loss of
-dystrobrevin in kidney and liver
and the loss of dystrophin in skeletal muscle is the effect of these
molecules on the localization of their ligands. In mdx and
DMD muscle, the absence of dystrophin leads to secondary loss of DPC
from the sarcolemma (8, 13, 17). Similarly, in kidney, the
loss of
-dystrobrevin from the basolateral region of epithelial
cells of cortical renal tubules and collecting tubules resulted in the
loss of Dp71
C and all three syntrophin isoforms. Likewise the
absence of
-dystrobrevin from liver sinusoids led to the secondary
loss of Dp71 isoforms and approximately two-thirds of
1-syntrophin
molecules. Therefore the membrane localization of these proteins in
kidney and liver requires the presence of
-dystrobrevin. Consistent
with this idea, the levels of Dp71 isoforms and
1-syntrophin were
reduced in microsome preparations of dtnb
/
kidneys and liver compared with those prepared from tissues of control
littermates. Since
-dystrobrevin and dystroglycan colocalize in both
tissues (6) (Fig. 3A and 4A) and dystrobrevin has been shown to bind to dystroglycan in vitro (5),
-dystrobrevin may serve to link interacting molecules to kidney and
liver basement membranes via an interaction with dystroglycan.
The function of
-dystrobrevin-containing protein complexes in kidney
and liver is not known. Based on work carried out on the dystrophin
complexes in skeletal muscle, we know that
-dystrobrevin may be
involved in intracellular signaling, either directly or through its
association with the syntrophins (9). Therefore, we
speculate that
-dystrobrevin may act as a scaffold for signaling molecules in a similar manner. Syntrophins recruit a variety of signaling molecules to the DPC via binding to their PDZ domains. Recently, we showed that the dystrobrevins, the dystrophin isoforms, and utrophin each contain two tandem syntrophin binding motifs (16). Thus the loss of
-dystrobrevin and Dp71
C and
the corresponding loss of the syntrophins from the basal membranes of
dtnb
/
renal tubules and liver suggest that
potentially up to four syntrophin-binding signaling molecules per
DPC-like complex fail to be recruited to the membrane. Despite its
expression in many nonmuscle tissues and its effect on its ligands in
kidney and liver, the normal appearance of the
dtnb
/
mice suggests that
-dystrobrevin is
not important for the viability of the mouse. An alternative
explanation is that, under normal physiological conditions, the effect
of
-dystrobrevin loss is masked, and the true effect of this loss
will only become evident when the renal or hepatic system of these mice
is challenged.
In conclusion, we have shown that
-dystrobrevin is required for the
assembly of Dp71 and syntrophin molecules to the basal membrane of
kidney cells and liver sinusoids, but its presence is not critical for
the survival of
-dystrobrevin-null mice.
| |
ACKNOWLEDGMENTS |
|---|
This work was funded by the Wellcome Trust. D.J.B. is a Wellcome Trust Senior Research Fellow.
We thank Sarah Squire, Allyson Potter, Adrian Isaacs, Mohan Masih, Lynne Scott, Karo Tanaka, and Nicholas Owen for advice and technical expertise.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Human Anatomy and Genetics, University of Oxford, South Parks Rd., Oxford OX1 3QX, United Kingdom. Phone: (1865) 272179. Fax: (1865) 272420. E-mail: kay.davies{at}human-anatomy.ox.ac.uk.
Present address: Nuffield Department of Clinical Medicine, John
Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, United Kingdom.
Present address: Deutsches Krcbsforschungszentrum Heidelberg,
Abteilung Molekularbiologie der Zelle 1, 69120 Heidelberg, Germany.
§ Present address: Department of Pharmacology, University of Oxford, Oxford OX1 3QT, United Kingdom.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Blake, D. J., and K. E. Davies. 1997. Dystrophin and the molecular genetics of muscular dystrophy, p. 219-241. In Y. H. Edwards, and D. M. Swallow (ed.), Protein dysfunction in human genetic diseases. BIOS Scientific, Oxford, United Kingdom. |
| 2. |
Blake, D. J.,
R. Hawkes,
M. A. Benson, and P. W. Beesley.
1999.
Different dystrophin-like complexes are expressed in neurons and glia.
J. Cell Biol.
147:645-658 |
| 3. |
Blake, D. J.,
R. Nawrotzki,
N. Y. Loh,
D. C. Gorecki, and K. E. Davies.
1998.
Beta-dystrobrevin, a member of the dystrophin-related protein family.
Proc. Natl. Acad. Sci. USA
95:241-246 |
| 4. |
Blake, D. J.,
R. Nawrotzki,
M. F. Peters,
S. C. Froehner, and K. E. Davies.
1996.
Isoform diversity of dystrobrevin, the murine 87-kDa postsynaptic protein.
J. Biol. Chem.
271:7802-7810 |
| 5. | Chung, W., and J. T. Campanelli. 1999. WW and EF hand domains of dystrophin-family proteins mediate dystroglycan binding. Mol. Cell Biol. Res. Commun. 2:162-171[CrossRef][Medline]. |
| 6. |
Durbeej, M.,
M. D. Henry,
M. Ferletta,
K. P. Campbell, and P. Ekblom.
1998.
Distribution of dystroglycan in normal adult mouse tissues.
J. Histochem. Cytochem.
46:449-457 |
| 7. | Dwyer, T. M., and S. C. Froehner. 1995. Direct binding of Torpedo syntrophin to dystrophin and the 87 kDa dystrophin homologue. FEBS Lett. 375:91-94[CrossRef][Medline]. |
| 8. | Ervasti, J. M., K. Ohlendieck, S. D. Kahl, M. G. Gaver, and K. P. Campbell. 1990. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345:315-319[CrossRef][Medline]. |
| 9. | Grady, R. M., R. W. Grange, K. S. Lau, M. M. Maimone, M. C. Nichol, J. T. Stull, and J. R. Sanes. 1999. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat. Cell Biol. 1:215-220[CrossRef][Medline]. |
| 10. | Grady, R. M., H. Zhou, J. M. Cunningham, M. D. Henry, K. P. Campbell, and J. R. Sanes. 2000. Maturation and maintenance of the neuromuscular synapse: genetic evidence for roles of the dystrophin-glycoprotein complex. Neuron 25:279-293[CrossRef][Medline]. |
| 11. | Loh, N. Y., H. J. Ambrose, L. M. Guay-Woodford, S. DasGupta, R. A. Nawrotzki, D. J. Blake, and K. E. Davies. 1998. Genomic organization and refined mapping of the mouse beta-dystrobrevin gene. Mamm. Genome 9:857-862[CrossRef][Medline]. |
| 12. | Loh, N. Y., S. E. Newey, K. E. Davies, and D. J. Blake. 2000. Assembly of multiple dystrobrevin-containing complexes in the kidney. J. Cell Sci. 113:2715-2724[Abstract]. |
| 13. | Matsumura, K., F. M. Tome, V. Ionasescu, J. M. Ervasti, R. D. Anderson, N. B. Romero, D. Simon, D. Recan, J. C. Kaplan, M. Fardeau, et al. 1993. Deficiency of dystrophin-associated proteins in Duchenne muscular dystrophy patients lacking COOH-terminal domains of dystrophin. J. Clin. Investig. 92:866-871. |
| 14. | Nawrotzki, R., N. Y. Loh, M. A. Ruegg, K. E. Davies, and D. J. Blake. 1998. Characterisation of alpha-dystrobrevin in muscle. J. Cell Sci. 111:2595-2605[Abstract]. |
| 15. | Nehls, M., B. Kyewski, M. Messerle, R. Waldschutz, K. Schuddekopf, A. J. Smith, and T. Boehm. 1996. Two genetically separable steps in the differentiation of thymic epithelium. Science 272:886-889[Abstract]. |
| 16. | Newey, S. E., M. A. Benson, C. P. Ponting, K. E. Davies, and D. J. Blake. 2000. Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex. Curr. Biol. 10:1295-1298[CrossRef][Medline]. |
| 17. |
Ohlendieck, K., and K. P. Campbell.
1991.
Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice.
J. Cell Biol.
115:1685-1694 |
| 18. |
Peters, M. F.,
K. F. O'Brien,
H. M. Sadoulet-Puccio,
L. M. Kunkel,
M. E. Adams, and S. C. Froehner.
1997.
Beta-dystrobrevin, a new member of the dystrophin family. Identification, cloning, and protein associations.
J. Biol. Chem.
272:31561-31569 |
| 19. |
Sadoulet-Puccio, H. M.,
T. S. Khurana,
J. B. Cohen, and L. M. Kunkel.
1996.
Cloning and characterization of the human homologue of a dystrophin related phosphoprotein found at the Torpedo electric organ post-synaptic membrane.
Hum. Mol. Genet.
5:489-496 |
| 20. |
Sadoulet-Puccio, H. M.,
M. Rajala, and L. M. Kunkel.
1997.
Dystrobrevin and dystrophin: an interaction through coiled-coil motifs.
Proc. Natl. Acad. Sci. USA
94:12413-12418 |
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»